핵의학

본문글자크기
  • [Clin Nucl Med .] A Phase 0 Microdosing PET/CT Study Using O-[18F]Fluoromethyl-d-Tyrosine in Normal Human Brain and Brain Tumor
    정상인과 뇌종양 환자에서의 FMT PET 0상 임상시험

    퓨쳐켐, KIRAMS / 문한솔, 지대윤*, 윤상민*, 임상무*

  • 출처
    Clin Nucl Med .
  • 등재일
    2021 Sep 1
  • 저널이슈번호
    46(9):717-722. doi: 10.1097/RLU.0000000000003735.
  • 내용

    바로가기  >

    Abstract
    Purpose: The aim of the present study was to obtain information about distribution, radiation dosimetry, toxicity, and pharmacokinetics of O-[18F]fluoromethyl-d-tyrosine (d-18F-FMT), an amino acid PET tracer, in patients with brain tumors.

    Patients and methods: A total of 6 healthy controls (age = 19-25 years, 3 males and 3 females) with brain PET images and radiation dosimetry and 12 patients (median age = 60 years, 6 males and 6 females) with primary (n = 5) or metastatic brain tumor (n = 7) were enrolled. We acquired 60-minute dynamic brain PET images after injecting 370 MBq of d-18F-FMT. Time-activity curves of d-18F-FMT uptake in normal brain versus brain tumors and tumor-to-background ratio were analyzed for each PET data set.

    Results: Normal cerebral uptake of d-18F-FMT decreased from 0 to 5 minutes after injection, but gradually increased from 10 to 60 minutes. Tumoral uptake of d-18F-FMT reached a peak before 30 minutes. Tumor-to-background ratio peaked at less than 15 minutes for 8 patients and more than 15 minutes for 4 patients. The mean effective dose was calculated to be 13.2 μSv/MBq.

    Conclusions: Using d-18F-FMT as a PET radiotracer is safe. It can distinguish brain tumor from surrounding normal brain tissues with a high contrast. Early-time PET images of brain tumors should be acquired because the tumor-to-background ratio tended to reach a peak within 15 minutes after injection.

     

     

    Affiliations

    Hansol Moon, Byung Hyun Byun 1, Ilhan Lim 1, Byung Il Kim 1, Chang Woon Choi 1, Chang Hun Rhee 2, Kyo Chul Lee 3, Sang-Keun Woo 3, Chansoo Park 4, Hee Seup Kil 4, Dae Yoon Chi 4, Sang Min Youn 2, Sang Moo Lim 1
    1Departments of Nuclear Medicine.
    2Neurosurgery, Korea Cancer Center Hospital.
    3Division of RI Convergence, Korea Institute of Radiological and Medical Sciences.
    4FutureChem Co, Ltd, Seoul, Republic of Korea.

  • 편집위원

    Aminoacid PET 추적자로 개발된 O-[18F]fluoromethyl-d-tyrosine (d-18F-FMT)의 뇌종양추적자로서의 가능성을 연구한 임상연구로 핵의학 임상가 및 뇌종양 관련 신경외과 임상의사에게 관심을 끌 연구로 생각됨.

    2021-10-19 14:48:27

  • 덧글달기
    덧글달기
       IP : 44.222.161.54

    등록